Experts are excitedly investigating retatrutide, a novel treatment from Eli Lilly, as a possible breakthrough in physique management. Unlike many previous approaches, retatrutide is a double -action agonist targeting both GLP-1 and GIP, hormones that impact satiety and blood sugar regulation . P